Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio che confronta Siplizumab con Globulina Anti-Timociti di Coniglio per aiutare l'organismo ad accettare un trapianto di rene (MODERNIZE1)

6 novembre 2026 aggiornato da: ITB-Med LLC

Studio di fase 2b, randomizzato, multicentrico, in doppio cieco, per la determinazione del dosaggio, controllato con attivo, di Siplizumab (TCD601) rispetto alla Globulina Anti-Timocita di Coniglio in riceventi di trapianto renale che richiedono terapia di induzione e ricevono la terapia immunosoppressiva standard con Tacrolimus, Acido Micofenolico e Corticosteroidi

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

Tipo di studio

Interventistico

Iscrizione (Stimato)

120

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasile, 30150-320
        • Reclutamento
        • Santa Casa Demisericordia de Belo Horizonte
        • Contatto:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasile, 90035-903
        • Reclutamento
        • Hospital de Clinicas de Porto Alegre
        • Contatto:
      • Porto Alegre, Rio Grande do Sul, Brasile, 90020-090
        • Reclutamento
        • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
        • Contatto:
    • São Paulo
      • São José do Rio Preto, São Paulo, Brasile, 15090-000
        • Reclutamento
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
        • Contatto:
      • São Paulo, São Paulo, Brasile, 04038-002
        • Reclutamento
        • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
        • Contatto:
      • Barcelona, Spagna, 08035
        • Reclutamento
        • Hospital Universitari Vall D'Hebron
        • Contatto:
      • Córdoba, Spagna, 14004
      • Málaga, Spagna, 29010
        • Reclutamento
        • Hospital Universitario Regional de Malaga
        • Contatto:
    • California
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • Keck Hospital of the University of Southern California
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90095
        • Reclutamento
        • University of California - Los Angeles, Connie Frank Kidney Transplant Center
        • Contatto:
      • Sacramento, California, Stati Uniti, 95817
        • Reclutamento
        • UC Davis Medical Center
        • Contatto:
    • Florida
      • Tampa, Florida, Stati Uniti, 33606
        • Reclutamento
        • Tampa General Hospital
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University Hospital
        • Contatto:
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • Reclutamento
        • University of Kansas Hospital
        • Contatto:
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • Reclutamento
        • University of Kentucky Healthcare
        • Contatto:
    • Louisiana
      • Metairie, Louisiana, Stati Uniti, 70006
        • Reclutamento
        • Tulane Medical Center
        • Contatto:
    • Massachusetts
      • Worcester, Massachusetts, Stati Uniti, 01655
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan - Michigan Medicine
        • Contatto:
          • Nerissa Reister, Clinical Research Coordinator
          • Numero di telefono: 734-763-5718
          • Email: naflow@med.umich.edu
      • Detroit, Michigan, Stati Uniti, 48202
        • Reclutamento
        • Henry Ford Health
        • Contatto:
    • New Jersey
      • Livingston, New Jersey, Stati Uniti, 07039
        • Reclutamento
        • Cooperman Barnabus Medical Center
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10032
        • Reclutamento
        • New York Presbyterian - Columbia University Irving Medical School
        • Investigatore principale:
          • Lloyd Ratner, MD
        • Contatto:
        • Contatto:
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • New York Presbyterian - Weill Cornell Medical Center
        • Contatto:
        • Contatto:
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center
        • Contatto:
    • Texas
      • Dallas, Texas, Stati Uniti, 75390
    • Virginia
      • Falls Church, Virginia, Stati Uniti, 22042
        • Reclutamento
        • Inova Fairfax Hospital
        • Contatto:
      • Richmond, Virginia, Stati Uniti, 23298
        • Reclutamento
        • Virginia Commonwealth University Health
        • Contatto:
    • Washington
      • Seattle, Washington, Stati Uniti, 98195
        • Reclutamento
        • University of Washington Medical Center
        • Contatto:
          • Belinda Pan, Research Coordinator
          • Numero di telefono: 206-598-1562
          • Email: bcpan@uw.edu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Bassa dose di siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Altri nomi:
  • TCD601
Sperimentale: Alta dose di siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Altri nomi:
  • TCD601
Comparatore attivo: Globulina anti-timociti di coniglio

An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Altri nomi:
  • Timoglobulina

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Lasso di tempo: 12 months

Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
  • Composite incidence of BPAR, death, graft loss, and loss-to-follow-up.
  • Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring).
  • Incidence of treated BPAR and steroid-resistant BPAR.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months

• Grade of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months

• Severity of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
  • Time to first BPAR for each participant.
  • Time to graft loss for each participant.
  • Time to death for each participant.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
  • Participant survival at 12 months.
  • Graft survival at 12 months.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months

• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

12 months
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Lasso di tempo: 12 weeks

Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Lasso di tempo: 12 weeks

Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Lasso di tempo: 12 months

Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 giugno 2026

Completamento primario (Stimato)

28 marzo 2028

Completamento dello studio (Stimato)

28 marzo 2028

Date di iscrizione allo studio

Primo inviato

11 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

27 marzo 2026

Primo Inserito (Effettivo)

2 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • TCD601B205

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .